keyword
MENU ▼
Read by QxMD icon Read
search

Multiple sclerosis treatments

keyword
https://www.readbyqxmd.com/read/29656444/predicting-therapeutic-response-to-fingolimod-treatment-in-multiple-sclerosis-patients
#1
Bibiana Quirant-Sánchez, José V Hervás-García, Aina Teniente-Serra, Luis Brieva, Ester Moral-Torres, Antonio Cano, Elvira Munteis, María J Mansilla, Silvia Presas-Rodriguez, Juan Navarro-Barriuso, Cristina Ramo-Tello, Eva M Martínez-Cáceres
AIMS: Fingolimod, an orally active immunomodulatory drug for relapsing-remitting multiple sclerosis (RRMS), sequesters T cells in lymph nodes through functional antagonism of the sphingosine-1-phosphate receptor, reducing the number of potential autoreactive cells that migrate to the central nervous system. However, not all RRMS patients respond to this therapy. Our aim was to test the hypothesis that by immune-monitoring RRMS patient's leukocyte subpopulations it is possible to find biomarkers associated with clinical response to fingolimod...
April 15, 2018: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/29656097/treatment-of-epilepsy-in-multiple-sclerosis
#2
Ioanna Dagiasi, Victor Vall, Eva Kumlien, Joachim Burman, Johan Zelano
PURPOSE: The prevalence of epilepsy is increased in multiple sclerosis (MS), but information on AED treatment and seizure outcome is scarce. We describe epilepsy characteristics including the use of AEDs and proportion of seizure-free patients at two tertiary hospitals in Sweden. METHOD: We retrospectively studied electronic medical records of all patients with a diagnosis of MS and seizures at Sahlgrenska university hospital and Uppsala university hospital. Clinical data were reviewed until 2017...
April 5, 2018: Seizure: the Journal of the British Epilepsy Association
https://www.readbyqxmd.com/read/29652832/sympathetic-nerve-hyperactivity-in-the-spleen-causal-for-nonpathogenic-driven-chronic-immune-mediated-inflammatory-diseases-imids
#3
REVIEW
Denise L Bellinger, Dianne Lorton
Immune-Mediated Inflammatory Diseases (IMIDs) is a descriptive term coined for an eclectic group of diseases or conditions that share common inflammatory pathways, and for which there is no definitive etiology. IMIDs affect the elderly most severely, with many older individuals having two or more IMIDs. These diseases include, but are not limited to, type-1 diabetes, obesity, hypertension, chronic pulmonary disease, coronary heart disease, inflammatory bowel disease, and autoimmunity, such as rheumatoid arthritis (RA), Sjőgren's syndrome, systemic lupus erythematosus, psoriasis, psoriatic arthritis, and multiple sclerosis...
April 13, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29652301/-the-results-of-an-open-comparative-retrospective-trial-of-the-course-of-multiple-sclerosis-during-treatment-with-infibeta-and-other-interferon-beta-bioanalogues-and-glatiramer-acetate
#4
F A Khabirov, T I Khaybullin, E V Granatov, S R Shakirzianova, N N Babicheva, O S Kochergina, E F Rakhmatullina, G M Akhmedova, L A Averyanova, M A Yakupov, Zh F Sabirov
AIM: To evaluate the efficacy and safety of the interferon beta-1b bioanalogue 'infibeta' in the treatment of multiple sclerosis (MS) in comparison with other interferon beta bioanalogues and the generic drug glatiramer acetate. MATERIAL AND METHODS: The data of 500 patients with MS treated with different disease-modifying drugs were analyzed. Patients of group 1 (n=95) received infibeta; group 2 (n=108) interferon beta-1b; group 3 (n=83) genfaxon-44; group 4 (n=109) sinnovex; group 5 (n=105) aksoglatiran FS...
2018: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29651709/-cannabinoid-therapy-in-practice
#5
REVIEW
T Rasche, D Emmert, C Stieber, M Mücke, R Conrad
BACKGROUND: In recent years, the media and scientists have shown increased interest in cannabis-based drugs. OBJECTIVES: Background information about cannabis-based drugs and their mechanism of action as well as discussion of possible applications as supportive therapy or in palliative medicine, respectively, are presented. MATERIALS AND METHODS: The recent literature was examined and evaluated. RESULTS: In many medical fields, we do not have sufficient evidence for the efficacy of cannabinoids...
April 12, 2018: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/29651206/urinary-urea-uric-acid-and-hippuric-acid-as-potential-biomarkers-in-multiple-sclerosis-patients
#6
Hanaa B Atya, Sahar A Ali, Mohamed I Hegazy, Fathia Z El Sharkawi
Urine is a proven source of metabolite biomarkers and has the potential to be a rapid, noninvasive, inexpensive, and efficient diagnostic tool for various human diseases. Despite these advantages, urine is an under-investigated source of biomarkers for multiple sclerosis (MS). The objective was to investigate the level of some urinary metabolites (urea, uric acid and hippuric acid) in patients with MS and correlate their levels to the severity of the disease, MS subtypes and MS treatment. The urine samples were collected from 73 MS patients-48 with RRMS and 25 with SPMS- and age matched 75 healthy controls...
April 2018: Indian Journal of Clinical Biochemistry: IJCB
https://www.readbyqxmd.com/read/29650331/spasmodic-dysphonia-in-multiple-sclerosis-treatment-with-botulin-toxin-a-a-pilot-study
#7
Arianna Di Stadio, Evanthia Bernitsas, Domenico Antonio Restivo, Enrico Alfonsi, Rosario Marchese-Ragona
OBJECTIVES: This study aims to evaluate the effect of botulin toxin A in patients with multiple sclerosis (MS) affected by spasmodic dysphonia (SD) and to show the safety and effectiveness of this treatment in long-term observation. MATERIALS AND METHODS: This is a pilot study on three relapsing-remitting MS patients with SD and their response to botulin toxin A. RESULTS: None of the patients reported dysphagia or other adverse events. Significant improvement was observed in terms of both voice quality and laryngostroboscopy results...
April 9, 2018: Journal of Voice: Official Journal of the Voice Foundation
https://www.readbyqxmd.com/read/29649930/pulmonary-paracoccidioidomycosis-associated-with-the-use-of-natalizumab-in-multiple-sclerosis
#8
Kelson James Almeida, Raissa Viera Barreto-Soares, Raimundo Nonato Campos-Sousa, Maria Graças Campos-Sousa, Edson Bor-Seng-Shu
BACKGROUND: Natalizumab (NTZ) is a monoclonal antibody with an immunosuppressive effect that reduces the inflammation of the central nervous system, and it has been used for the treatment of relapsing-remitting multiple sclerosis (RRMS). In patients with low cellular immune response, systemic mycosis arising from endemic areas may occur. RESULTS AND CONCLUSION: In this article, we will describe a case of paracoccidioidomycosis as a complication to treatment with NTZ in an RRMS patient...
April 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29649789/improving-fatigue-in-multiple-sclerosis-by-smartphone-supported-energy-management-the-ms-telecoach-feasibility-study
#9
Marie D'hooghe, Geert Van Gassen, Daphne Kos, Olivier Bouquiaux, Melissa Cambron, Danny Decoo, Andreas Lysandropoulos, Bart Van Wijmeersch, Barbara Willekens, Iris-Katharina Penner, Guy Nagels
BACKGROUND: Fatigue is a frequently occurring, often disabling symptom in MS with no single effective treatment. In current fatigue management interventions, personalized, real-time follow-up is often lacking. The objective of the study is to assess the feasibility of the MS TeleCoach, a novel intervention offering telemonitoring of fatigue and telecoaching of physical activity and energy management in persons with MS (pwMS) over a 12-week period. The goal of the MS TeleCoach, conceived as a combination of monitoring, self-management and motivational messages, is to enhance levels of physical activity thereby improving fatigue in pwMS in an accessible and interactive way, reinforcing self-management of patients...
March 27, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29648900/no-evidence-of-disease-activity-in-patients-receiving-fingolimod-at-private-or-academic-centers-in-clinical-practice-a-retrospective-analysis-of-the-multiple-sclerosis-clinical-and-magnetic-resonance-imaging-outcomes-in-the-usa-ms-mrius-study
#10
Robert Zivadinov, Nasreen Khan, Jonathan R Korn, Ellen Lathi, Jason Silversteen, Jonathan Calkwood, Scott Kolodny, Diego Silva, Jennie Medin, Bianca Weinstock-Guttman
OBJECTIVE: The impact of multiple sclerosis (MS) center type on outcomes has not been investigated. This study aimed to evaluate baseline characteristics and clinical and magnetic resonance imaging (MRI) outcomes in patients with MS receiving fingolimod over 16 months' follow-up at private or academic centers in the USA. METHODS: Clinical and MRI data collected in clinical practice from patients initiating fingolimod were stratified by center type and retrospectively analyzed...
April 12, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29645067/-new-drugs-for-the-treatment-of-multiple-sclerosis
#11
EDITORIAL
J Rio
No abstract text is available yet for this article.
April 16, 2018: Revista de Neurologia
https://www.readbyqxmd.com/read/29643001/immune-cell-bdnf-expression-in-treatment-na%C3%A3-ve-relapsing-remitting-multiple-sclerosis-patients-and-following-one-year-of-immunomodulation-therapy
#12
Alicja Kalinowska-Łyszczarz, Mikołaj A Pawlak, Aleksandra Wyciszkiewicz, Krystyna Osztynowicz, Wojciech Kozubski, Sławomir Michalak
Although neurons are the main source of neurotrophins in the healthy brain, neurotrophins can also be expressed in the immune system. We have previously shown that in relapsing-remitting multiple sclerosis (RRMS) lower immune-cell neurotrophin levels are associated with brain atrophy and cognitive impairment. The aim of the present study was to assess if immune-cell neurotrophin expression is impaired in MS as compared with the healthy controls, and to describe if these levels change in treatment-naïve RRMS patients, following one year of immunomodulation...
March 29, 2018: Neurologia i Neurochirurgia Polska
https://www.readbyqxmd.com/read/29629942/paediatric-multiple-sclerosis-and-other-acute-demyelinating-diseases
#13
Kevin Rostásy, Barbara Bajer-Kornek
PURPOSE OF REVIEW: Neuroimmunological diseases encompass a wide spectrum of diseases in children. Apart from the discovery of autoantibodies affecting primarily grey matter structures and the improved clinical characterization of rare entities such as N-methyl D-aspartate receptor-R- encephalitis, important strides have also been made in autoimmune-mediated white matter diseases, including paediatric multiple sclerosis (pedMS) and other acute demyelinating syndromes (ADS) often associated with antibodies (abs) against myelin-oligodendrocyte-glycoprotein (MOG)...
April 7, 2018: Current Opinion in Neurology
https://www.readbyqxmd.com/read/29629902/humanized-mouse-model-of-rasmussen-s-encephalitis-supports-the-immune-mediated-hypothesis
#14
Hania Kebir, Lionel Carmant, François Fontaine, Kathie Béland, Ciprian M Bosoi, Nathalie T Sanon, Jorge I Alvarez, Sébastien Desgent, Camille L Pittet, David Hébert, Marie-Josée Langlois, Rose-Marie Rébillard, Dang K Nguyen, Cécile Cieuta-Walti, Gregory L Holmes, Howard P Goodkin, John R Mytinger, Mary B Connolly, Alexandre Prat, Elie Haddad
Rasmussen's encephalitis (RE) is a chronic inflammatory brain disorder that causes frequent seizures and unilateral hemispheric atrophy with progressive neurological deficits. Hemispherectomy remains the only treatment that leads to seizure freedom for this refractory epileptic syndrome. The absence of an animal model of disease has been a major obstacle hampering the development of effective therapies. Here, we describe an experimental mouse model that shares several clinical and pathological features with the human disease...
April 9, 2018: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29629605/ectrims-actrims-2017-closing-in-on-neurorepair-in-progressive-multiple-sclerosis
#15
David Kremer, Patrick Küry, Hans-Peter Hartung
BACKGROUND: While there is now a multitude of potent medications for relapsing-remitting multiple sclerosis (RRMS), effective therapies targeting neurodegeneration in progressive multiple sclerosis types are still lacking. Stimulation of neurorepair in this disease remains a pathogenetically defined treatment goal. However, therapeutic progress is slowed by the still inadequate tool set to capture "regeneration/repair" in MS and to define appropriate outcomes in clinical trials...
April 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29629601/occipital-neuralgia-associates-with-high-cervical-spinal-cord-lesions-in-idiopathic-inflammatory-demyelinating-disease
#16
Narayan R Kissoon, James C Watson, Christopher J Boes, Orhun H Kantarci
Background The association of trigeminal neuralgia with pontine lesions has been well documented in multiple sclerosis, and we tested the hypothesis that occipital neuralgia in multiple sclerosis is associated with high cervical spinal cord lesions. Methods We retrospectively reviewed the records of 29 patients diagnosed with both occipital neuralgia and demyelinating disease by a neurologist from January 2001 to December 2014. We collected data on demographics, clinical findings, presence of C2-3 demyelinating lesions, and treatment responses...
January 1, 2018: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/29629575/adult-hospital-admissions-associated-with-multiple-sclerosis-in-finland-in-2004-2014
#17
Anna-Leena Pirttisalo, Jussi O T Sipilä, Merja Soilu-Hänninen, Päivi Rautava, Ville Kytö
INTRODUCTION: Treatment of multiple sclerosis (MS) has developed significantly and several new immunotherapeutic drugs have become available in Finland since 2004. We studied whether this is associated with changes in hospital admission frequencies and healthcare costs and whether admission rates due to infection have increased. METHODS: The national Care Register for Health Care was searched for all discharges from neurological, medical, surgical, neurosurgical and intensive care units with MS as a primary diagnosis or an auxiliary diagnosis for primary infection diagnosis in 2004-2014...
April 9, 2018: Annals of Medicine
https://www.readbyqxmd.com/read/29627873/disease-modifying-treatment-in-progressive-multiple-sclerosis
#18
REVIEW
John Robert Ciotti, Anne Haney Cross
PURPOSE OF REVIEW: Multiple sclerosis (MS) is an immune-mediated disorder that affects the central nervous system (CNS), often first affecting people in early adulthood. Although most MS patients have a relapsing-remitting course (RRMS) at disease onset, a substantial proportion later develop chronic progression, termed secondary progressive MS (SPMS). Approximately 10% of MS patients experience chronic progression from disease onset, termed primary progressive multiple sclerosis (PPMS)...
April 7, 2018: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/29627017/effect-of-teriflunomide-on-gray-and-white-matter-brain-pathology-in-multiple-sclerosis-using-volumetric-and-diffusion-tensor-imaging-mri-measures
#19
Robert Zivadinov, Niels Bergsland, Jesper Hagemeier, Ellen Carl, Hanna Kolb, David Hojnacki, Bianca Weinstock-Guttman
OBJECTIVES: To investigate the effect of teriflunomide on microstructural pathology in the gray matter (GM) and white matter (WM), as measured by changes in brain volume and diffusion-tensor imaging (DTI) in patients with multiple sclerosis (MS). METHODS: 30 relapsing MS patients and 20 healthy controls (HCs) were enrolled in the study and followed prospectively for 12 months with clinical and 3T MRI examinations. Of those, 26 MS patients and 18 HCs completed the 6-month and 22 MS and 16 HCs patients the 12-month follow-up...
May 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29627016/real-world-persistence-with-fingolimod-for-the-treatment-of-multiple-sclerosis-a-systematic-review-and-meta-analysis
#20
Daniel Kantor, Kristen Johnson, Maria Cecilia Vieira, James Signorovitch, Nanxin Li, Wei Gao, Valerie Koo, Emilie Duchesneau, Vivian Herrera
OBJECTIVE: To systematically review reports of fingolimod persistence in the treatment of relapsing-remitting multiple sclerosis (RRMS) across data sources and practice settings, and to develop a consensus estimate of the 1-year real-world persistence rate. METHODS: A systematic literature review was conducted (MEDLINE, EMBASE, and abstracts from selected conferences [2013-2015]) to identify observational studies reporting 1-year fingolimod persistence among adult patients with RRMS (sample size ≥50)...
May 15, 2018: Journal of the Neurological Sciences
keyword
keyword
114918
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"